⌕
Novartis · NVS · NYSE
Tenet 55 · Mixed
Compare
$159.13−0.67%At closeTenet 55 · Mixed
$159.13−1.07 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Novartis (NVS) Stock

Novartis (NVS) closed at $159.13 on Nov 17, 2026; its Tenet Score is 55 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$159.13
Nov 17, 2026
Market cap
$305.7B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
21.9×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
Dividend yield
2.96%
past year's regular dividends ÷ price · as of close, Nov 16, 2026
52-week range
123.24 – 170.46
low → high · as of close, Nov 16, 2026
Tenet Score
55/100
Mixed · 340 Healthcare peers

Industry: Drugs

Novartis AG scores 55/100. Mixed. Strongest on quality, financial health is the soft spot, trading at 22× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
57
Quality
77
Health
30
Growth
58

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthDGrowthCMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
6.6×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/S
5.4×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
31%
fiscal year to Dec 31, 2025
Operating margin
31.1%
before interest and tax
Net margin
24.6%
fiscal year to Dec 31, 2025
Current ratio
1.12
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not reported in the company's filings for this period.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 51 US ETFs · top wrappers by weightSee all ETFs holding NVS →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Johnson & JohnsonJNJ48$680.2B
Abbvie IncABBV42$520.7B
Merck & Co IncMRK41$356.1B
AMGEN Inc.AMGN47$250.1B
Gilead Sciences, Inc.GILD38$207.9B
Novo NordiskNVO62$185.7B
Pfizer Inc.PFE50$164.5B
Vertex Pharmaceuticals, Inc.VRTX55$136.4B
Bristol-Myers Squibb Co.BMY51$128.6B
GSK PlcGSK51$108.8B

Compare Novartis with

What sector and industry is Novartis in?

Novartis is in the Healthcare sector and the Drugs industry.

What is Novartis' Tenet Score?

Novartis' Tenet Score is 55 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.